glp-1 drugs and addiction How Can Agonists Be Used in Treatment? GLP-1 drugs linked to lower
Description
Insights may cover the historical clinical development of Glucagon-like Peptide-1 (GLP-1) Agonists, their mechanism of action, their subtypes and future commercial prospects
Physiologic release of incretins also causes postprandial blood glucose reduction by reducing circulating glycogen and increasing insulin
A major role of the hormone is to regulate the glucose homeostasis in a glucose-dependent manner as a result of its insulinotropic and glucagonostatic actions
It can lead to dehydration, malnutrition, and hospitalization
